Precision NanoSystems, Inc. Launches Commercial SUB9KIT Reagents at Leading Neuroscience Conference

Press Release

November 09, 2013

VANCOUVER, British Columbia, Canada – Precision NanoSystems, Inc. (PNI), a privately held biotechnology company developing proprietary microfluidic-based manufacturing technology for the use and development of cutting edge nanomedicines, today launched its commercial SUB9KITSTM reagents at the Society for Neuroscience (SFN) meeting.  The Annual SFN meeting is the industry leading conference for molecular neuroscientists, attracting over 30,000 scientists and industry leaders.

PNI will be launching its Neuro9KIT, specifically designed for the study of genes in diseases of the brain.  Additionally, PNI has been invited to present data on the Neuro9KIT at the conference in a talk entitled “ApoE-Enhanced Lipid Nanoparticle Delivery of siRNA Silences Neuronal Gene Expression in vitro & in vivo”. PNI will provide interested customers demonstration Neuro9KITS that fluoresce when administered into neuronal cells, allowing users to rapidly assess the effectiveness of the kit in their given model of disease.

Dr. James Taylor, Chief Executive Officer of PNI, commented, “The Annual SFN conference is the largest scientific meeting related to the brain and the neuroscience.  PNI is very excited to launch our neuroscience specific SUB9KITTM, the Neuro9KIT, at the conference and to begin working with neuroscientists to accelerate their understanding of the brain diseases that greatly affect our society. The invitation by the SFN committee to give a podium presentation highlights the latent need for innovative tools, like the Neuro9KIT, to accelerate molecular neuroscience research.”

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.

About SUB9KITSTM

SUB9KITSTM enable medical researchers to study the role of genes in disease faster and more effectively.  SUB9KITSTM deliver genetic materials, like DNA and RNA, into to cells to turn genes under study on or off in models of disease.  This allows medical researchers to reverse engineer the cellular pathways that, when genetically changed, cause disease.  Adapted from nanomedicine technology currently in clinical trials, SUB9KITSTM allow delivery in models of disease that are more reflective of human illness, including models cancers, neurodegneration, rare genetic disorders, and others.  SUB9KITSTM is a Precision NanoSystems brand.  For more information please visit: http://sub9kits.com/

About the 2013 Society for Neuroscience Annual Meeting

Neuroscience 2013 is the world’s largest meeting focused on scientific discovery related to the brain and nervous system.  The event is expected to bring to life more than 15,000 scientific presentations showing innovative advances in techniques and valuable new research about brain structure, health, disease, and treatments. In addition to the posters and scientific lectures, the meeting featured 34 professional development workshops and networking functions, and 600 exhibitors.


IN THE NEWS

Press Release

Vancouver, British Columbia– Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectious disease, today announce...

Read More


Press Release

Vancouver, British Columbia, March 8, 2017 – Precision NanoSystems has launched the NanoAssemblr™ Scale-Up system to support the clinical development of nanomedicines. This latest addition to the NanoAssemblr range is designed for the m...

Read More


MENU
菜单
X
X